alveoair® has received U.S. FDA clearance, marking a significant advancement in respiratory care
Specializing in digital therapeutics for respiratory care, the company is committed to delivering affordable and interoperable lung health solutions.
- Specializing in digital therapeutics for respiratory care, the company is committed to delivering affordable and interoperable lung health solutions.
- This U.S. FDA approval, coupled with strategic partnerships like the one with AstraZeneca, positions alveofit® for broader international expansion, particularly in the U.S. and emerging economies.
- Since achieving CDSCO certification in India in June 2022, alveoair® has been adopted by over 400 healthcare facilities across India.
- Earlier this year, to cater to the growing U.S. market, alveofit® inaugurated its office in New York.